Ophthalmic Patents (Class 514/912)
-
Patent number: 8637070Abstract: Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.Type: GrantFiled: February 9, 2006Date of Patent: January 28, 2014Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Sreenivasu Mudumba, Philippe J M Dor, Thierry Nivaggioli, David A. Weber, Sidiq Farooq
-
Patent number: 8633181Abstract: This invention concerns a method of treating hemangiomas with a beta blocker by applying the beta blocker onto the hemangiomas directly. The invention also concerns a combination therapy by using a beta blocker along with a corticosteroid or an alpha adrenergic receptor agonist for the treatment of hemangiomas.Type: GrantFiled: April 9, 2010Date of Patent: January 21, 2014Assignee: Rutgers, The State University of New JerseyInventor: Suqin Guo
-
Patent number: 8618088Abstract: The present invention relates to compositions and methods for inhibiting unwanted angiogenesis, particularly those of ocular tissues. The treatment, inhibition, and/or prevention of choroidal neovasculature (CNV) is provided, along with an animal model for CNV and imaging techniques that permit the screening of potential agents as anti-angiogenesis and anti-CNV agents.Type: GrantFiled: March 29, 2012Date of Patent: December 31, 2013Assignee: University of PennsylvaniaInventors: Rong Wen, Zhijun Luo, Alan M. Laties
-
Patent number: 8614235Abstract: The subject invention provides CAI compounds and formulations thereof, and methods for their use in the localized treatment of non-life threatening diseases. Formulations of CAI compounds of the subject invention include CAI free base and CAI prodrug microcrystallines, microparticles, emulsions, and the like. The subject invention further provides methods for treating non-life threatening diseases using the CAI compounds of the invention (i.e., novel delivery systems and combination therapies) that are effective and are associated with little or no adverse side effects.Type: GrantFiled: July 13, 2011Date of Patent: December 24, 2013Assignee: RFE Pharma LLCInventors: Gary Robinson, Gideon Shapiro, Alan J. Franklin, Simona Jurczyk
-
Patent number: 8592450Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.Type: GrantFiled: February 16, 2012Date of Patent: November 26, 2013Assignee: SARcode Bioscience Inc.Inventors: Thomas Gadek, John Burnier
-
Patent number: 8585938Abstract: UV absorbing compounds that are effective in blocking UV and short-wavelength blue light are disclosed. The UV absorbing compounds are particularly suitable for use in intraocular lens materials.Type: GrantFiled: March 29, 2013Date of Patent: November 19, 2013Assignee: Novartis AGInventors: David L. Jinkerson, Walter R. Laredo
-
Patent number: 8580789Abstract: Provided herein are methods of protecting all or a portion of the optic nerve fiber layer within the optic nerve/lamina cribrosa (ONLC) complex in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's peripapillary sclera, thereby stiffening the individual's peripapillary sclera and protecting all or a portion of the optic nerve fiber layer within the ONLC of the individual. In a particular embodiment, the invention is directed to methods of treating glaucoma in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's peripapillary sclera, thereby stiffening the individual's peripapillary sclera and treating the glaucoma in the individual.Type: GrantFiled: April 2, 2008Date of Patent: November 12, 2013Assignees: The Cleveland Clinic FoundationInventors: Ronald R. Krueger, William J. Dupps, Stephen Trokel, Ivey Thornton
-
Patent number: 8580851Abstract: The present invention relates to an ophthalmic solution comprising a prostaglandin compound and viscosity-increasing compound. The ophthalmic solution of the invention is excellent in stability and can provide long lasting and increased effect when administrated topically to the eyes of a patient.Type: GrantFiled: April 21, 2005Date of Patent: November 12, 2013Assignee: Sucampo AGInventor: Ryuji Ueno
-
Patent number: 8568790Abstract: The present invention relates to medicinal compositions containing a honey having non peroxide antibacterial activity and wherein the composition comprises from about 19% to about 80% water by weight. The use of these compositions in the treatment of eye, respiratory and ear conditions is also disclosed.Type: GrantFiled: May 31, 2007Date of Patent: October 29, 2013Assignee: Medihoney Pty Ltd.Inventor: Anthony Peter Moloney
-
Patent number: 8557868Abstract: The present invention relates to a lens care solution comprising: 0.001 to about 5 weight percent of a low molecular weight amine of the general formula: Where R1, R2, R3 and R4 are —H or low molecular weight radicals, and R5 is a low molecular weight radical, or salt thereof; an effective amount of tonicity agent; and the balance water.Type: GrantFiled: November 14, 2002Date of Patent: October 15, 2013Assignee: FXS Ventures, LLCInventor: Francis X. Smith
-
Patent number: 8551974Abstract: Ophthalmic compositions are provided that include a lubricant, a deturgescent agent, a glycosaminoglycan, and water. Methods of using the ophthalmic compositions are also provided.Type: GrantFiled: June 11, 2010Date of Patent: October 8, 2013Inventor: Richard L. Lindstrom
-
Patent number: 8541413Abstract: This invention provides for biocompatible, biodegradable eye drop pharmaceutical formulations useful for the treatment of ocular indications. In particular, tocopherols and their esters of low water solubility, notably ?-tocopheryl acetate, are exceptional vehicles for biocompatible, nonirritating topical eye drop formulations that provide sustained release of active agents.Type: GrantFiled: September 24, 2008Date of Patent: September 24, 2013Assignee: Ramscor, Inc.Inventors: Vernon G. Wong, Louis L. Wood
-
Patent number: 8541463Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.Type: GrantFiled: January 14, 2013Date of Patent: September 24, 2013Assignee: Allergan Sales, LLCInventors: Christopher A. Muller, Janet K. Cheetham, Teresa H. Kuan, David F. Power
-
Patent number: 8536190Abstract: The present invention provides compositions and uses of an ascomycin macrolactam for the treatment of an unwanted ocular condition occurring in a patient undergoing treatment with a therapeutically active agent for the treatment of cancer.Type: GrantFiled: January 16, 2008Date of Patent: September 17, 2013Assignee: Allergan, Inc.Inventor: Rhett M. Schiffman
-
Patent number: 8536167Abstract: The present invention relates to methods for treating an ophthalmic, otic, or nasal infection comprising treating the infected tissue with a composition comprising finafloxacin or a finafloxacin derivative. The present invention also relates to antimicrobial compositions comprising finafloxacin or a finafloxacin derivative. The compositions are suitable for the treatment of ophthalmic, otic, or nasal infections.Type: GrantFiled: July 2, 2010Date of Patent: September 17, 2013Assignee: Alcon Research, Ltd.Inventors: David W. Stroman, Masood A. Chowhan, Kenneth C. Appell
-
Patent number: 8529907Abstract: Provided is a method for improving day photopic vision and/or cone-derived visual field and visual function in a subject suffering from a retinal disease or trauma including administering to the subject a pharmaceutically effective amount of crude Dunaliella powder. Also provided is a method for improving night vision and/or rod derived visual field in a subject suffering from a retinal disease including administering to the subject a pharmaceutically effective amount of crude Dunaliella powder. A pharmaceutical composition for improving day vision and/or visual field in a subject suffering from a retinal disease including crude Dunaliella powder is also provided.Type: GrantFiled: April 27, 2009Date of Patent: September 10, 2013Assignees: Nikken Sohonsha Corporation, Tel Hashomer Medical Research Infrastructure and Services Ltd.Inventors: Michael Belkin, Aviv Shaish, Dror Harats, Ygal Rotenstreich
-
Patent number: 8529927Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.Type: GrantFiled: March 31, 2006Date of Patent: September 10, 2013Assignee: Allergan, Inc.Inventors: James N. Chang, Lon T. Spada, Wendy M. Blanda, Werhner C. Orilla, James A. Burke, Patrick M. Hughes
-
Patent number: 8530449Abstract: The present invention is directed to a topical ophthalmic composition for a liquid comprised of clear colloidal polar nanolipids delivered in submicron sized particles (Nanopids™), aqueous colloidal lubricants, aqueous polymers, emulsifies, and a unique stabilizing buffer system, which undergoes a liquid-gel phase transition in the eye. Said composition is designed to deliver advanced eye lubricants, protect the three (3) layers of corneal film from dryness, and provide a unique system of Dry Eye treatment that addresses and treats all three layers of corneal tear film. Said composition is further designed to provide a superior delivery system of various Active Pharmaceutical Ingredients (APIs), and/or anti-infective/antibiotic/anti-fungal agents, accepted as safe and efficacious for ophthalmic use.Type: GrantFiled: September 9, 2010Date of Patent: September 10, 2013Inventor: Assad S. Sawaya
-
Patent number: 8524758Abstract: Ophthalmic compositions for the treatment of presbyopia, including combinations of parasympathomimetics and non-steroidal anti-inflammatories.Type: GrantFiled: December 6, 2007Date of Patent: September 3, 2013Inventor: Jorge Luis Benozzi
-
Patent number: 8518996Abstract: An aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof and an organic amine (for example, aminoethylsulfonic acid or trometamol) or a salt thereof is useful as an eye drop for once a day administration for treating inflammatory diseases of the external segment or the anterior segment of the eyes, since such aqueous eye drop can maintain a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in anterior aqueous humor for at least 24 hours by once a day administration.Type: GrantFiled: September 14, 2012Date of Patent: August 27, 2013Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Shirou Sawa, Tomoko Fujimoto
-
Patent number: 8506986Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.Type: GrantFiled: January 31, 2008Date of Patent: August 13, 2013Assignee: Allergan, Inc.Inventors: Glenn T Huang, Brittany Jackson, James A. Burke, Ton Lin, Patrick M. Hughes, Larry A. Wheeler, Rosy Sheng Donn
-
Patent number: 8501800Abstract: An ophthalmically acceptable vehicle includes an aqueous suspension having a first viscosity. The suspension includes about 0.1% to about 6.5% by weight of a carboxyl-containing polymer prepared by polymerizing one or more carboxyl-containing monoethylenically unsaturated monomers and less than about 5% by weight of a cross-linking agent. The polymer has average particle size of not more than about 50 ?m in equivalent spherical diameter. The vehicle includes a second polymer that allows the carboxyl-containing polymer to remain suspended. Upon contact with tear fluid, the vehicle gels to a second viscosity which is greater than the first viscosity. A method of administering a medicament to the eye of a subject includes applying a composition that includes this ophthalmically acceptable vehicle and a medicament contained for treatment of a disease or disorder for which ophthalmic delivery is indicated. The medicament is released from the vehicle in a sustained release manner.Type: GrantFiled: March 5, 2009Date of Patent: August 6, 2013Assignee: Insite Vision IncorporatedInventors: Lyle Bowman, Stephen Pham
-
Patent number: 8501789Abstract: This invention relates to methods for treating age-related macular degeneration, blindness or glaucoma using an iron-chelator SIH.Type: GrantFiled: January 18, 2008Date of Patent: August 6, 2013Assignee: The Trustees of the University of PennsylvaniaInventor: Joshua L. Dunaief
-
Patent number: 8460743Abstract: The present invention generally relates to a method for coating ophthalmic lenses, preferably contact lenses, more preferably silicone hydrogel contact lenses. In particular, the present invention is directed to a method for forming a coating comprising a polyionic material on a contact lens, preferably a silicone hydrogel contact lens, directly in the primary package and maintaining the coated contact lens within said primary package until insertion of the coated contact lens in the eye of the contact lens user.Type: GrantFiled: March 16, 2009Date of Patent: June 11, 2013Assignee: Novartis AGInventors: Achim Müller, Katharina Schmid
-
Patent number: 8455494Abstract: This application relates to the use of one or more parasympathomimetic drugs in combination with one or more alpha agonists to create optically beneficial miosis to, for example, temporarily treat presbyopia. The invention provides a pharmaceutical preparation comprising a therapeutically effective amount of one or more parasympathomimetic drugs or cholinesterase inhibitors, or a pharmaceutically acceptable salt thereof, in combination with one or more alpha agonists or antagonists, or a pharmaceutically acceptable salt thereof. The invention further provides for a method for treating, ameliorating or reducing presbyopia of a patient having an eye, comprising administering to said eye a pharmaceutically effective amount of the ophthalmic preparation.Type: GrantFiled: September 6, 2012Date of Patent: June 4, 2013Assignee: HEK Development, LLCInventor: Herbert E. Kaufman
-
Patent number: 8455492Abstract: The present invention provides a method of providing neuroprotection to a mammal comprising administering to said mammal suffering from or at risk of suffering a noxious action on its nerve cells an effective amount of a compound of formula I to inhibit or prevent nerve cell injury or death wherein the 2-imidazolin-2-ylamino group is in either the 5- or 6-position of the quinoxaline nucleus; x, y and z are in any of the remaining 5-, 6-, 7- or 8-positions and are selected from hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl; and R is an optional substituent in either the 2- or 3-position of the quinoxaline nucleus and may be hydrogen, lower alkyl or lower alkoxy, or pharmaceutically acceptable salts thereof and mixtures thereof. Such noxious action may result from ischemia, e.g. spinal ischemia.Type: GrantFiled: December 7, 2005Date of Patent: June 4, 2013Assignee: Allergan, Inc.Inventors: Larry A. Wheeler, Elizabeth Woldemussie, Ronald K. Lai
-
Patent number: 8450287Abstract: Ophthalmic pharmaceutical compositions containing tobramycin, dexamethasone and deacetylated xanthan gum are described. The compositions provide longer ocular retention for enhanced ocular bioavailability of tobramycin and dexamethasone. In a preferred embodiment, the compositions also provide for improved suspension of dexamethasone. The concentration of ionizable species in the compositions is controlled so as to prevent precipitation of the xanthan gum as a result of ionic interactions between tobramycin and xanthan gum, while allowing for a restoration of viscosity upon topical application of the compositions to the eye. The use of deacetylated xanthan gum is disclosed, so as to avoid formulation instability caused by pH drift during storage.Type: GrantFiled: December 6, 2011Date of Patent: May 28, 2013Assignee: Alcon Research, Ltd.Inventor: Bhagwati P. Kabra
-
Patent number: 8425891Abstract: Dihydroxybenzotriazole UV absorbing compounds that are particularly useful in ophthalmic devices are disclosed.Type: GrantFiled: October 15, 2012Date of Patent: April 23, 2013Assignee: Novartis AGInventor: David L. Jinkerson
-
Patent number: 8420699Abstract: Therapeutically effective compositions and methods to inhibit dry eye as well as other conditions are provided. A therapeutically effective composition consists of at least one surfactant; a preservative with reduced immunogenicity relative to thimerosol; a complexing agent; and deionized, demineralized, ozonated water.Type: GrantFiled: October 31, 2011Date of Patent: April 16, 2013Inventor: Irvine L. Dubow
-
Patent number: 8388941Abstract: The use of a borate/polyol and zinc system to enhance the antimicrobial activity of multi-dose pharmaceutical compositions is described. The compositions do not require a conventional anti-microbial preservative and therefore are referred to as being ‘self-preserved’. The compositions possess sufficient antimicrobial activity to satisfy the preservative efficacy requirements of the USP for aqueous ophthalmic compositions.Type: GrantFiled: September 20, 2007Date of Patent: March 5, 2013Assignee: Alcon Research, Ltd.Inventors: Masood A. Chowhan, David J. Keith
-
Patent number: 8377982Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.Type: GrantFiled: March 30, 2012Date of Patent: February 19, 2013Assignee: Allergan Sales, LLCInventors: Christopher A. Muller, Janet K. Cheetam, Teresa H. Kuan
-
Patent number: 8324271Abstract: An eye drop composition in which the degradation of isopropyl unoprostone in an eye drop is prevented by adding trometamol to the eye drop containing isopropyl unoprostone.Type: GrantFiled: July 28, 2011Date of Patent: December 4, 2012Assignee: R-Tech Ueno, Ltd.Inventors: Hiroyuki Asada, Akio Kimura
-
Patent number: 8324171Abstract: Ophthalmic composition that includes 0.05% w/v to 2% w/v diglycine or a salt thereof; 1.0 ppm to 8.5 ppm alexidine, and 0.1% w/v to 2% w/v of one or more boron buffering compounds.Type: GrantFiled: February 6, 2012Date of Patent: December 4, 2012Assignee: Bausch & Lomb IncorporatedInventors: Susan E. Burke, Erning Xia, Catherine A. Scheuer, Srini Venkatesh
-
Patent number: 8323630Abstract: The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borate or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred.Type: GrantFiled: April 14, 2011Date of Patent: December 4, 2012Assignee: Alcon Research, Ltd.Inventors: Bhagwati P. Kabra, Masood A. Chowhan, L. Wayne Schneider, Wesley Wehsin Han
-
Patent number: 8323631Abstract: Dihydroxybenzotriazole UV absorbing compounds that are particularly useful in ophthalmic devices are disclosed.Type: GrantFiled: July 19, 2011Date of Patent: December 4, 2012Assignee: Novartis AGInventor: David L. Jinkerson
-
Patent number: 8318741Abstract: The present invention relates in general to therapeutic compositions and methods of use. In preferred embodiments, the invention relates to the field of eye health. In some embodiments, the invention relates to the prevention and treatment of macular degeneration by administering compounds disclosed herein. In some embodiments, the invention relates to compositions and methods of improving vision.Type: GrantFiled: April 5, 2012Date of Patent: November 27, 2012Assignee: The Texas A & M University SystemInventor: George C. Chiou
-
Patent number: 8318739Abstract: The present invention provides a method for treating a corneal disease by administering to a patient in need of such treatment an effective amount of ozagrel or a salt thereof.Type: GrantFiled: July 1, 2010Date of Patent: November 27, 2012Assignee: Teika Pharmaceutical Co., Ltd.Inventors: Takahito Kimura, Shigeto Fujishita, Hiroyoshi Kawada
-
Patent number: 8314118Abstract: This invention relates to treatment of dry eye. In particular, the invention relates to methods and formulations for treating dry eye based on topical application of opioid antagonists such as naltrexone.Type: GrantFiled: April 15, 2010Date of Patent: November 20, 2012Inventors: Ian S. Zagon, Patricia J. McLaughlin, Joseph W. Sassani
-
Patent number: 8309612Abstract: An object of the present invention is to find a novel medicinal use of 2-phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof. 2-Phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof exhibits an excellent inhibitory effect on neovascularization in the choroid and also has a protective effect on retinal pigment epithelial cell damage, and therefore is useful as a prophylactic or therapeutic agent for age-related macular degeneration.Type: GrantFiled: May 23, 2008Date of Patent: November 13, 2012Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Shin-ichiro Hirai, Atsushi Yoshida
-
Patent number: 8299124Abstract: An aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof and an organic amine (for example, aminoethylsulfonic acid or trometamol) or a salt thereof is useful as an eye drop for once a day administration for treating inflammatory diseases of the external segment or the anterior segment of the eyes, since such aqueous eye drop can maintain a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in anterior aqueous humor for at least 24 hours by once a day administration.Type: GrantFiled: December 21, 2011Date of Patent: October 30, 2012Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Shirou Sawa, Tomoko Fujimoto
-
Patent number: 8293741Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others or to improve vision in a normal eye.Type: GrantFiled: April 29, 2005Date of Patent: October 23, 2012Assignee: Allergan, Inc.Inventors: James A. Burke, Patrick M. Hughes, Kai-Ming Zhang, Ton Lin, Glenn Huang, Brittany A. Jackson, Larry A. Wheeler, Rosy S. Donn
-
Patent number: 8268824Abstract: A therapeutic agent for a corneal disease comprising irsogladine or a salt thereof as an active ingredient. The purpose is to find a substance capable of effectively treating/ameliorating a corneal disease which has been increased in the number of cases thereof in recent years and to provide a therapeutic agent for a corneal disease comprising the substance as an active ingredient.Type: GrantFiled: January 12, 2010Date of Patent: September 18, 2012Assignee: Teika Pharmaceutical Co., Ltd.Inventors: Takahito Kimura, Shigeto Fujishita, Hiroyoshi Kawada
-
Patent number: 8268299Abstract: The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borat or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred.Type: GrantFiled: September 20, 2007Date of Patent: September 18, 2012Assignee: Alcon Research, Ltd.Inventors: Bhagwati P. Kabra, Masood A. Chowhan, L. Wayne Schneider, Wesley Wehsin Han
-
Patent number: 8262948Abstract: Disclosed are ophthalmic device materials having improved light transmission characteristics. The materials contain a combination of certain UV absorbers and blue-light absorbing chromophores.Type: GrantFiled: April 27, 2011Date of Patent: September 11, 2012Assignee: Novartis AGInventors: Walter R. Laredo, Ali E. Akinay
-
Patent number: 8262947Abstract: Benzotriazole UV/Visible light-absorbing monomers are disclosed. The UV/Vis absorbers are particularly suitable for use in intraocular lens materials.Type: GrantFiled: July 2, 2010Date of Patent: September 11, 2012Assignee: Novartis AGInventor: Walter R. Laredo
-
Patent number: 8239978Abstract: Photodynamic therapy of conditions of the eye, especially those conditions characterized by unwanted neovasculature, such as age-related macular degeneration, results in enhanced visual acuity for treated subjects.Type: GrantFiled: September 10, 2007Date of Patent: August 14, 2012Assignee: Novartis Opthalmics AGInventors: H. Andrew Strong, Julia G. Levy, Gustav Huber, Mario Fsadni
-
Patent number: 8222283Abstract: An object of the present invention is to provide a new medicinal use of 2-phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof. 2-Phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof exhibits an excellent prevention and improvement effect in corneal disorder models, and is therefore useful as a preventive or therapeutic agent for a keratoconjunctival disorder such as dry eye, superficial punctate keratopathy, corneal epithelial defects, corneal erosion, corneal ulcer, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, keratitis or conjunctivitis.Type: GrantFiled: May 17, 2006Date of Patent: July 17, 2012Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Atsushi Yoshida, Shinichirou Hirai, Masatsugu Nakamura
-
Patent number: 8216603Abstract: A method, device, and system for easier, consistent, and comfortable delivery of therapeutic agents to the front of the eye.Type: GrantFiled: May 4, 2007Date of Patent: July 10, 2012Inventor: Herbert Edward Kaufman
-
Patent number: 8211942Abstract: Compositions and methods to inhibit dry eye as well as other conditions are provided.Type: GrantFiled: January 26, 2011Date of Patent: July 3, 2012Inventor: Irvine L. Dubow
-
Patent number: 8211880Abstract: Triamcinolone acetonide suspension compositions are disclosed. The suspension compositions have a relatively low viscosity and are easy to extrude through a 27- or 30-guage needle but are highly flocculated and easily redispersed. The compositions are particularly suitable for intravitreal injection.Type: GrantFiled: January 17, 2012Date of Patent: July 3, 2012Assignee: Alcon Research, Ltd.Inventors: Bhagwati P. Kabra, Ruma Sarkar